Search results
After bruising year, GSK approaches consumer split in better health
Reuters via Yahoo Finance· 2 years agoThings are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to...
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Zacks via Yahoo Finance· 2 months agoStrong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and...
GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view
Reuters via Yahoo Finance· 1 year ago(Reuters) - Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper...
GSK attacks ‘meritless claims’ over heartburn drug Zantac
The Independent via Yahoo News· 2 years agoGSK and its consumer spin-off brand Haleon have hit back at market speculation over heartburn drug...
GSK consumer spin-off Haleon floats in biggest London listing in a decade
The Independent via Yahoo News· 2 years agoGlaxoSmithKline’s consumer spin-off Haleon has floated on the London Stock Exchange in Europe’s...
FTSE 100: GSK raises guidance after strong demand for shingles vaccine
Yahoo Finance UK· 2 years agoSales of the Shingrix vaccine by GSK have more than doubled to £731m. Photo: Reuters/Loriene Perera...
FTSE 100: GSK loses £4.5bn in value on Zantac lawsuit concerns
Yahoo Finance UK· 2 years agoGSK lost billions in value amid litigation concerns over the heartburn drug Zantac. Photo: Drew...
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
Zacks via Yahoo Finance· 10 months agoGSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK...
GSK spinoff Haleon has no deals on immediate horizon
Reuters via Yahoo Finance· 1 year agoConsumer healthcare group Haleon's Chief Executive Brian McNamara said on Thursday he does not expect to announce any acquisitions or divestments...
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine
Zacks via Yahoo Finance· 2 years agoThis week, AstraZeneca AZN and Sanofi’s SNY RSV vaccine, nirsevimab and Sanofi and GSK’s GSK...